ClinicalTrials.gg
Not yet recruitingNCT07492836HipoGBMUpdated Mar 25, 2026

Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma

An interventional study of Hypofractionated Radiation Therapy in Glioblastoma (GBM), sponsored by Hospital do Coracao. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Hospital do Coracao · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the feasibility, safety and effectiveness of radiotherapy with fewer days of treatment and a higher dose of radiation each day in patients under 70 years of age diagnosed with a brain tumor known as glioblastoma.

Read the detailed description

The goal of this clinical trial is to evaluate the feasibility (accrual of patients, planning of radiotherapy), safety (acute and late neurological toxicity) and effectiveness (overall survival and progression free survival) of radiotherapy with fewer days of treatment and a higher dose of radiation each day (dose of 60 Gy in 20 fractions of 3 Gy) in patients between 18 and 70 years of age diagnosed with a brain tumor known as glioblastoma. Additionally, circulating tumor cells will be searched in the blood before and after radiotherapy and its quantitative and qualitative analysis will be correlated with the survival outcomes.

02

Conditions studied

  • Glioblastoma (GBM)

Browse trials for

Keywords

  • Radiotherapy
  • Temozolamide
03

In context

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 10 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Hospital do Coracao is the lead sponsor of 67 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Initial histological diagnosis of glioblastoma
  • Age > 18 and \< 70 years;
  • Performance Status > 70%;
  • Patient consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients submitted to any type of previous radiotherapy in the cranial region;
  • Multicentric tumors;
  • to chemotherapy with temozolomide;
  • Contraindications for performing magnetic resonance imaging (MRI), such as the use of implants or metallic prostheses;
  • Pregnant women or women of childbearing age who refuse to undergo the beta-HCG test before treatment and during the intervention.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Single arm

    Hypofractonated Radiotherapy

    Radiation: Hypofractionated Radiation Therapy

Interventions

  • RadiationHypofractionated Radiation Therapy

    60 Gy in 20 fractions of 3 Gy

06

What researchers measure

Primary outcomes

  1. Feasibility of accrual and planning

    Accrual of patients, timely and adequated planning of radiotherapy

    Time frame: From enrollment to the end of planning of the 10 patients at 5 months

  2. Incidence of acute and late neurological toxicity

    Incidence of headache, brain edema and brain radionecrosis will be classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Weekly evaluation during treatment and at 4, 12, 24, 36 weeks in the first year and every 6 months until 3 years after radiotherapy.

Secondary outcomes

  1. Overall Survival and Progression Free Survival

    Death from any cause and disease progression during treatment and follow-up time

    Time frame: Start of radiotherapy to the date of event (death or progression of disease) up tp 3 years

Other outcomes

  1. Correlative science

    Evaluation of circulating tumor cells in the blood

    Time frame: Before and 4 to 6 weeks after radiotherapy

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Muller Bark J, Kulasinghe A, Hartel G, Leo P, Warkiani ME, Jeffree RL, Chua B, Day BW, Punyadeera C. Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology - A Pilot Study. Front Oncol. 2021 Jun 3;11:681130. doi: 10.3389/fonc.2021.681130. eCollection 2021. PubMed 34150645 ↗
  • Mallick S, Gupta S, Amariyil A, Kunhiparambath H, Laviraj MA, Sharma S, Sagiraju HKR, Julka PK, Sharma D, Rath GK. Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial. J Neurooncol. 2023 Aug;164(1):141-146. doi: 10.1007/s11060-023-04391-7. Epub 2023 Jul 15. PubMed 37452916 ↗
  • Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38. PubMed 23425509 ↗

Individual participant data

Plan to share: Yes — All IPD collected throughout the trial,

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 6 months after publication with no end date

Access criteria: A proposal that describes planned analyses must be submitted by a researcher with a history of publishing on the topic

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2026, 6 months later.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 6 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 25, 2026
StartEst.
Apr 2026
Primary completionEst.
Oct 2026
CompletionEst.
Apr 2029
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07492836
Lead sponsor
Hospital do Coracao
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Apr 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Apr 2029 (estimated)
Last update
Mar 25, 2026

Study contacts

Alexandre B Cavalcanti, MD PhD
Contact
abiasi@hcor.com.br
55 11 3053 6611
Karina L Negrelli, VMD
Contact
knegrelli@hcor.com.br
55 11 3053 6611
Douglas G Castro, MD PhD
principal investigator · Hospital do Coracao

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion